Compare CALC & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALC | FRSX |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 4.8M |
| IPO Year | 2020 | 2016 |
| Metric | CALC | FRSX |
|---|---|---|
| Price | $0.63 | $2.09 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 121.5K | 42.0K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.31 |
| 52 Week High | $7.20 | $3.00 |
| Indicator | CALC | FRSX |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 43.18 |
| Support Level | $0.50 | $0.83 |
| Resistance Level | $0.78 | $2.33 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 58.91 | 38.75 |
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
Foresight Autonomous Holdings Ltd is a technology company engaged in the development of 3D perception systems and cellular-based applications. The company designs, develops, and commercializes in-line-of-sight vision systems and beyond-line-of-sight accident prevention solutions through its subsidiaries. Its solutions are based on stereo vision, 3D perception, and V2X technologies, aimed at improving safety by enabling accurate obstacle detection and real-time alerts. The company targets multiple industries, including automotive, defense, agriculture, and heavy equipment.